All-Oral Regimen for AML Provides New Treatment Pathway
From Medical Industry Feature · 00:02:45
Show by ReachMD
Guest: Gail J. Roboz, M.D. Gail J. Roboz, M.D., director of the Clinical and Translational Leukemia Program at NewYork-Presbyterian and Weill Cornell Medicine, discusses a recent clinical trial for acute myeloid leukemia (AML) that resulted in FDA approval of an all-oral treatment regimen for newly diagnosed older patients and those who cannot tolerate intensive chemotherapy. The trial established safety and efficacy by developing patient-tailored scheduling and dosing modifications to optimize outcomes. The new oral regimen improves convenience of care by eliminating the need for in-person infusions and is creating more opportunities for patients who may not have otherwise been candidates to undergo potentially curative stem cell transplantation.
More episodes of Medical Industry Feature
More episodes
- PPV vs Phacovitrectomy for RRD in Phakic Eyes
- Can Metformin Use Cut Wet AMD Risk?
- Socioeconomic Determinants and Outcomes in Proliferative Sickle Retinopathy
- Single-Port Robotics Improves Outcomes for Thoracic Surgery
- Vitreous Hemorrhage Following PVD: Who Needs Surgery?
- Groundbreaking Gene Therapy Restores Natural Hearing for Genetic Deafness
- Help Protect Your Older Patients This Flu Season: Examining Real-World Data
- Climate Change and Skin Health: Challenges and Adaptive Strategies
- Challenges in AI-Driven Dermatology: Understanding Current Limitations
- AI and Hair Loss: Measuring Progress with Data-Driven Insights
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.